{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:08:16Z","timestamp":1788635296511,"version":"build-2803163510"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T00:00:00Z","timestamp":1685232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T00:00:00Z","timestamp":1685232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Geriatr Med"],"DOI":"10.1007\/s41999-023-00798-7","type":"journal-article","created":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T09:01:40Z","timestamp":1685264500000},"page":"733-746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review"],"prefix":"10.1007","volume":"14","author":[{"given":"Birkan","family":"\u0130lhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011fba","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Topinkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5343-9795","authenticated-orcid":false,"given":"G\u00fclistan","family":"Bahat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the EuGMS Task and Finish Group on FRIDs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,28]]},"reference":[{"key":"798_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1097\/EDE.0b013e3181e89905","volume":"21","author":"S Deandrea","year":"2010","unstructured":"Deandrea S, Lucenteforte E, Bravi F et al (2010) Risk factors for falls in community-dwelling older people: a systematic review and meta-analysis. Epidemiology 21:658\u2013668","journal-title":"Epidemiology"},{"key":"798_CR2","first-page":"771","volume":"57","author":"T Al-Aama","year":"2011","unstructured":"Al-Aama T (2011) Falls in the elderly: spectrum and prevention. Can Fam Physician 57:771\u2013776","journal-title":"Can Fam Physician"},{"key":"798_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/928603","volume":"2013","author":"M Chiara","year":"2013","unstructured":"Chiara M, Gianluigi G, Pasquale A et al (2013) Unexplained falls are frequent in patients with fall-related injury admitted to orthopaedic wards: the UFO study (unexplained falls in older patients). Curr Gerontol Geriatr Res 2013:928603","journal-title":"Curr Gerontol Geriatr Res"},{"key":"798_CR4","unstructured":"National Institute for Health and Care Excellence (NICE) (2015) Falls in older people"},{"key":"798_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37\u201349","journal-title":"Urology"},{"key":"798_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40266-020-00777-8","volume":"37","author":"C Shaw","year":"2020","unstructured":"Shaw C, Wagg A (2020) Overactive bladder in frail older adults. Drugs Aging 37:559\u2013565","journal-title":"Drugs Aging"},{"key":"798_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/j.1532-5415.1998.tb02469.x","volume":"46","author":"D Thom","year":"1998","unstructured":"Thom D (1998) Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 46:473\u2013480","journal-title":"J Am Geriatr Soc"},{"key":"798_CR8","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.juro.2010.05.093","volume":"184","author":"H Nakagawa","year":"2010","unstructured":"Nakagawa H, Niu K, Hozawa A et al (2010) Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J Urol 184:1413\u20131418","journal-title":"J Urol"},{"key":"798_CR9","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1002\/nau.23719","volume":"37","author":"R Jayadevappa","year":"2018","unstructured":"Jayadevappa R, Chhatre S, Newman DK et al (2018) Association between overactive bladder treatment and falls among older adults. Neurourol Urodyn 37:2688\u20132694","journal-title":"Neurourol Urodyn"},{"key":"798_CR10","unstructured":"Wagg AS CL, Johnson T et al (2017) Incontinence in the frail elderly. In: Abrams P CL, Wagg A, Wein A (eds) Incontinence, 6th Edition"},{"key":"798_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13207","volume":"73","author":"CC Chuang","year":"2019","unstructured":"Chuang CC, Yang E, Zou KH et al (2019) Health and functional status, health events, use of healthcare services and costs associated with overactive bladder among the medically complex vulnerable elderly in the US. Int J Clin Pract 73:e13207","journal-title":"Int J Clin Pract"},{"key":"798_CR12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1532-5415.2000.tb04744.x","volume":"48","author":"JS Brown","year":"2000","unstructured":"Brown JS, Vittinghoff E, Wyman JF et al (2000) Urinary incontinence: does it increase risk for falls and fractures? Study of osteoporotic fractures research group. J Am Geriatr Soc 48:721\u2013725","journal-title":"J Am Geriatr Soc"},{"key":"798_CR13","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s12325-018-0796-8","volume":"35","author":"SM Szabo","year":"2018","unstructured":"Szabo SM, Gooch KL, Walker DR et al (2018) The association between overactive bladder and falls and fractures: a systematic review. Adv Ther 35:1831\u20131841","journal-title":"Adv Ther"},{"key":"798_CR14","first-page":"2","volume":"12","author":"KLGD Josephson","year":"2004","unstructured":"Josephson KLGD (2004) Key considerations when treating the older patient with symptoms of urinary frequency and urgency. Ann Long-Term Care 12:2","journal-title":"Ann Long-Term Care"},{"key":"798_CR15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40266-018-0522-x","volume":"35","author":"AR Green","year":"2018","unstructured":"Green AR, Reifler LM, Boyd CM et al (2018) Medication profiles of patients with cognitive impairment and high anticholinergic burden. Drugs Aging 35:223\u2013232","journal-title":"Drugs Aging"},{"key":"798_CR16","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/03007995.2021.1920899","volume":"37","author":"N Kachru","year":"2021","unstructured":"Kachru N, Holmes HM, Johnson ML et al (2021) Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Curr Med Res Opin 37:1303\u20131313","journal-title":"Curr Med Res Opin"},{"key":"798_CR17","doi-asserted-by":"publisher","first-page":"S384","DOI":"10.1016\/j.jval.2019.04.1873","volume":"22","author":"S Sura","year":"2019","unstructured":"Sura S, Aparasu R (2019) PUK19 overactive bladder patients in the nursing homes: resident characteristics and treatment pattern. Value in Health 22:S384","journal-title":"Value in Health"},{"key":"798_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40266-018-0577-8","volume":"35","author":"A Wagg","year":"2018","unstructured":"Wagg A (2018) Anticholinergics for overactive bladder in frail and medically complex older people: the case for. Drugs Aging 35:777\u2013780","journal-title":"Drugs Aging"},{"key":"798_CR19","first-page":"7","volume":"168","author":"P Boyle","year":"1995","unstructured":"Boyle P, Napalkov P (1995) The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl 168:7\u201312","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"798_CR20","doi-asserted-by":"crossref","unstructured":"Committee AUAPG. 2003 AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 170: 530\u2013547","DOI":"10.1097\/01.ju.0000078083.38675.79"},{"key":"798_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1464-410X.2008.08317.x","volume":"104","author":"JK Parsons","year":"2009","unstructured":"Parsons JK, Mougey J, Lambert L et al (2009) Lower urinary tract symptoms increase the risk of falls in older men. BJU Int 104:63\u201368","journal-title":"BJU Int"},{"key":"798_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jash.2011.08.008","volume":"6","author":"C Feldstein","year":"2012","unstructured":"Feldstein C, Weder AB (2012) Orthostatic hypotension: a common, serious and underrecognized problem in hospitalized patients. J Am Soc Hypertens 6:27\u201339","journal-title":"J Am Soc Hypertens"},{"key":"798_CR23","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.2146\/ajhp090611","volume":"67","author":"SM Lavsa","year":"2010","unstructured":"Lavsa SM, Fabian TJ, Saul MI et al (2010) Influence of medications and diagnoses on fall risk in psychiatric inpatients. Am J Health Syst Pharm 67:1274\u20131280","journal-title":"Am J Health Syst Pharm"},{"key":"798_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1365-2710.2005.00629.x","volume":"30","author":"IO Poon","year":"2005","unstructured":"Poon IO, Braun U (2005) High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans. J Clin Pharm Ther 30:173\u2013178","journal-title":"J Clin Pharm Ther"},{"issue":"Suppl 1","key":"798_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000049872","volume":"40","author":"A Bertaccini","year":"2001","unstructured":"Bertaccini A, Vassallo F, Martino F et al (2001) Symptoms, bothersomeness and quality of life in patients with LUTS suggestive of BPH. Eur Urol 40(Suppl 1):13\u201318","journal-title":"Eur Urol"},{"key":"798_CR26","unstructured":"Lukacz ES (2021) Urgency urinary incontinence\/overactive bladder (OAB) in females: Treatment. In. UpToDate"},{"key":"798_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/SPV.0000000000001008","volume":"27","author":"Clinical Consensus Statement","year":"2021","unstructured":"Clinical Consensus Statement (2021) Association of anticholinergic medication use and cognition in women with overactive bladder. Female Pelvic Med Reconstr Surg 27:69\u201371","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"798_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11934-020-01003-z","volume":"21","author":"C Fogaing","year":"2020","unstructured":"Fogaing C, Mossa AH, Campeau L (2020) Are beta 3 adrenergic agonists now the preferred pharmacologic management of overactive bladder? Curr Urol Rep 21:49","journal-title":"Curr Urol Rep"},{"key":"798_CR29","unstructured":"From the American Association of Neurological Surgeons ASoNC, Interventional Radiology Society of Europe CIRACoNSESoMINTESoNESOSfCA, Interventions SoIRSoNS et al (2018) Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke 13: 612\u2013632"},{"key":"798_CR30","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1007\/s11606-020-05634-3","volume":"35","author":"N Kachru","year":"2020","unstructured":"Kachru N, Holmes HM, Johnson ML et al (2020) Risk of mortality associated with non-selective antimuscarinic medications in older adults with dementia: a retrospective study. J Gen Intern Med 35:2084\u20132093","journal-title":"J Gen Intern Med"},{"key":"798_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5213\/inj.1734850.425","volume":"21","author":"KE Andersson","year":"2017","unstructured":"Andersson KE (2017) On the site and mechanism of action of beta3-adrenoceptor agonists in the bladder. Int Neurourol J 21:6\u201311","journal-title":"Int Neurourol J"},{"key":"798_CR32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12877-020-1474-7","volume":"20","author":"TL Griebling","year":"2020","unstructured":"Griebling TL, Campbell NL, Mangel J et al (2020) Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr 20:109","journal-title":"BMC Geriatr"},{"key":"798_CR33","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.eururo.2017.12.031","volume":"73","author":"AK Nambiar","year":"2018","unstructured":"Nambiar AK, Bosch R, Cruz F et al (2018) EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol 73:596\u2013609","journal-title":"Eur Urol"},{"key":"798_CR34","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/JU.0000000000000309","volume":"202","author":"DJ Lightner","year":"2019","unstructured":"Lightner DJ, Gomelsky A, Souter L, Vasavada SP (2019) Diagnosis and treatment of overactive bladder (Non-neurogenic) in adults: AUA\/SUFU guideline amendment 2019. J Urol 202:558\u2013563","journal-title":"J Urol"},{"key":"798_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/nau.23309","volume":"37","author":"KD Kistler","year":"2018","unstructured":"Kistler KD, Xu Y, Zou KH et al (2018) Systematic literature review of clinical trials evaluating pharmacotherapy for overactive bladder in elderly patients: an assessment of trial quality. Neurourol Urodyn 37:54\u201366","journal-title":"Neurourol Urodyn"},{"key":"798_CR36","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.eururo.2012.08.060","volume":"62","author":"N Buser","year":"2012","unstructured":"Buser N, Ivic S, Kessler TM et al (2012) Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 62:1040\u20131060","journal-title":"Eur Urol"},{"key":"798_CR37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bju.12678","volume":"114","author":"C Chapple","year":"2014","unstructured":"Chapple C, Schneider T, Haab F et al (2014) Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU Int 114:418\u2013426","journal-title":"BJU Int"},{"key":"798_CR38","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/ijcp.12464","volume":"68","author":"SA Kaplan","year":"2014","unstructured":"Kaplan SA, Cardozo L, Herschorn S et al (2014) Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER. Int J Clin Pract 68:1065\u20131073","journal-title":"Int J Clin Pract"},{"key":"798_CR39","first-page":"S66","volume":"12","author":"W Stewart","year":"2001","unstructured":"Stewart W, Corey R, Herzog A et al (2001) Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynecol J 12:S66","journal-title":"Int Urogynecol J"},{"key":"798_CR40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1517\/14740338.2013.813016","volume":"12","author":"GM Rosa","year":"2013","unstructured":"Rosa GM, Bauckneht M, Scala C et al (2013) Cardiovascular effects of antimuscarinic agents in overactive bladder. Expert Opin Drug Saf 12:815\u2013827","journal-title":"Expert Opin Drug Saf"},{"key":"798_CR41","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","volume":"100","author":"P Abrams","year":"2007","unstructured":"Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987\u20131006","journal-title":"BJU Int"},{"key":"798_CR42","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1755-5949.2011.00248.x","volume":"18","author":"M Chancellor","year":"2012","unstructured":"Chancellor M, Boone T (2012) Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther 18:167\u2013174","journal-title":"CNS Neurosci Ther"},{"key":"798_CR43","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S0006-8993(97)01554-0","volume":"787","author":"N Ishizaka","year":"1998","unstructured":"Ishizaka N, Noda M, Yokoyama S et al (1998) Muscarinic acetylcholine receptor subtypes in the human iris. Brain Res 787:344\u2013347","journal-title":"Brain Res"},{"key":"798_CR44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1365-2125.2010.03813.x","volume":"72","author":"KE Andersson","year":"2011","unstructured":"Andersson KE, Campeau L, Olshansky B (2011) Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol 72:186\u2013196","journal-title":"Br J Clin Pharmacol"},{"key":"798_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-020-1474-7","volume":"20","author":"TL Griebling","year":"2020","unstructured":"Griebling TL, Campbell NL, Mangel J et al (2020) Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr 20:1\u201310","journal-title":"BMC Geriatr"},{"issue":"67","key":"798_CR46","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"2019","author":"By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society","year":"2019","unstructured":"By the American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society (2019) Updated AGS beers criteria(R) for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019(67):674\u2013694","journal-title":"J Am Geriatr Soc"},{"key":"798_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/ageing\/afu145","volume":"44","author":"D O'Mahony","year":"2014","unstructured":"O\u2019Mahony D, O\u2019Sullivan D, Byrne S et al (2014) STOPP\/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 44:213\u2013218","journal-title":"Age Ageing"},{"key":"798_CR48","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s41999-020-00297-z","volume":"11","author":"G Bahat","year":"2020","unstructured":"Bahat G, Ilhan B, Erdogan T et al (2020) Turkish inappropriate medication use in the elderly (TIME) criteria to improve prescribing in older adults: TIME-to-STOP\/TIME-to-START. Eur Geriatr Med 11:491\u2013498","journal-title":"Eur Geriatr Med"},{"key":"798_CR49","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40266-021-00855-5","volume":"38","author":"G Bahat","year":"2021","unstructured":"Bahat G, Ilhan B, Erdogan T et al (2021) International validation of the Turkish inappropriate medication use in the elderly (time) criteria set: a Delphi panel study. Drugs Aging 38:513\u2013521","journal-title":"Drugs Aging"},{"key":"798_CR50","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jamda.2013.03.008","volume":"14","author":"DC Moga","year":"2013","unstructured":"Moga DC, Carnahan RM, Lund BC et al (2013) Risks and benefits of bladder antimuscarinics among elderly residents of Veterans Affairs Community Living Centers. J Am Med Dir Assoc 14:749\u2013760","journal-title":"J Am Med Dir Assoc"},{"key":"798_CR51","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1532-5415.2008.01680.x","volume":"56","author":"TE Lackner","year":"2008","unstructured":"Lackner TE, Wyman JF, McCarthy TC et al (2008) Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc 56:862\u2013870","journal-title":"J Am Geriatr Soc"},{"key":"798_CR52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40801-020-00181-z","volume":"7","author":"AR Green","year":"2020","unstructured":"Green AR, Segal J, Boyd CM et al (2020) Patterns of potentially inappropriate bladder antimuscarinic use in people with dementia: a retrospective cohort study. Drugs-Real World Outcomes 7:151\u2013159","journal-title":"Drugs-Real World Outcomes"},{"key":"798_CR53","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/jcph.1067","volume":"58","author":"LT Kao","year":"2018","unstructured":"Kao LT, Huang CY, Lin HC, Chu CM (2018) No increased risk of fracture in patients receiving antimuscarinics for overactive bladder syndrome: a retrospective cohort study. J Clin Pharmacol 58:727\u2013732","journal-title":"J Clin Pharmacol"},{"key":"798_CR54","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/gps.5467","volume":"36","author":"N Kachru","year":"2021","unstructured":"Kachru N, Holmes HM, Johnson ML et al (2021) Comparative risk of adverse outcomes associated with nonselective and selective antimuscarinic medications in older adults with dementia and overactive bladder. Int J Geriatr Psychiatry 36:684\u2013696","journal-title":"Int J Geriatr Psychiatry"},{"key":"798_CR55","doi-asserted-by":"publisher","first-page":"030006052110429","DOI":"10.1177\/03000605211042994","volume":"49","author":"N Yang","year":"2021","unstructured":"Yang N, Wu Q, Xu F, Zhang X (2021) Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis. J Int Med Res 49:03000605211042994","journal-title":"J Int Med Res"},{"key":"798_CR56","doi-asserted-by":"crossref","unstructured":"Mostafaei H, Salehi-Pourmehr H, Jilch S et al (2021) Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: a systematic review and network meta-analysis. Eur Urol Focus","DOI":"10.1016\/j.euf.2021.08.011"},{"key":"798_CR57","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.archger.2016.11.006","volume":"69","author":"SM Vouri","year":"2017","unstructured":"Vouri SM, Kebodeaux CD, Stranges PM, Teshome BF (2017) Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr 69:77\u201396","journal-title":"Arch Gerontol Geriatr"},{"key":"798_CR58","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1464-410X.2009.09073.x","volume":"106","author":"KE Andersson","year":"2010","unstructured":"Andersson KE, Sarawate C, Kahler KH et al (2010) Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int 106:268\u2013274","journal-title":"BJU Int"},{"key":"798_CR59","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-3-642-23274-9_13","volume":"2","author":"RD Harvey","year":"2012","unstructured":"Harvey RD (2012) Muscarinic receptor agonists and antagonists: effects on cardiovascular function. Muscarin Recep 2:299\u2013316","journal-title":"Muscarin Recep"},{"key":"798_CR60","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1517\/17425255.2012.714365","volume":"8","author":"U Leone Roberti Maggiore","year":"2012","unstructured":"Leone Roberti Maggiore U, Salvatore S, Alessandri F et al (2012) Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Exp Opin Drug Metab Toxicol 8:1387\u20131408","journal-title":"Exp Opin Drug Metab Toxicol"},{"key":"798_CR61","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1177\/0091270005279010","volume":"45","author":"DB Serra","year":"2005","unstructured":"Serra DB, Affrime MB, Bedigian MP et al (2005) QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 45:1038\u20131047","journal-title":"J Clin Pharmacol"},{"key":"798_CR62","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1016\/j.juro.2007.08.033","volume":"178","author":"VW Nitti","year":"2007","unstructured":"Nitti VW, Dmochowski R, Sand PK et al (2007) Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 178:2488\u20132494","journal-title":"J Urol"},{"key":"798_CR63","doi-asserted-by":"publisher","first-page":"309","DOI":"10.5414\/CPP48309","volume":"48","author":"B Malhotra","year":"2010","unstructured":"Malhotra B, Wood N, Sachse R, Gandelman K (2010) Thorough QT study of the effect of fesoterodine on cardiac repolarization. Int J Clin Pharmacol Ther 48:309\u2013318","journal-title":"Int J Clin Pharmacol Ther"},{"key":"798_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/tcrm.1.2.157.62912","volume":"1","author":"DR Guay","year":"2005","unstructured":"Guay DR (2005) Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Clin Risk Manag 1:157","journal-title":"Ther Clin Risk Manag"},{"key":"798_CR65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2125.1996.tb00161.x","volume":"41","author":"R Hussain","year":"1996","unstructured":"Hussain R, Hartigan-Go K, Thomas S, Ford G (1996) Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 41:73\u201375","journal-title":"Br J Clin Pharmacol"},{"key":"798_CR66","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/00005344-200002000-00024","volume":"35","author":"SE Jones","year":"2000","unstructured":"Jones SE, Kasamaki Y, Shuba LM et al (2000) Analysis of the electrophysiologic effects of short-term oxybutynin on guinea pig and rabbit ventricular cells. J Cardiovasc Pharmacol 35:334\u2013340","journal-title":"J Cardiovasc Pharmacol"},{"key":"798_CR67","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/j.1365-2125.2008.03298.x","volume":"66","author":"H Asajima","year":"2008","unstructured":"Asajima H, Sekiguchi Y, Matsushima S et al (2008) QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman. Br J Clin Pharmacol 66:896","journal-title":"Br J Clin Pharmacol"},{"key":"798_CR68","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1517\/17425250902762866","volume":"5","author":"S Hoffstetter","year":"2009","unstructured":"Hoffstetter S, Che LF (2009) Solifenacin succinate for the treatment of overactive bladder. Expert Opin Drug Metab Toxicol 5:345\u2013350","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"798_CR69","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1124\/jpet.103.062182","volume":"308","author":"J Kang","year":"2004","unstructured":"Kang J, Chen X-L, Wang H et al (2004) Cardiac ion channel effects of tolterodine. J Pharmacol Exp Ther 308:935\u2013940","journal-title":"J Pharmacol Exp Ther"},{"key":"798_CR70","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/sj.clpt.6100089","volume":"81","author":"B Malhotra","year":"2007","unstructured":"Malhotra B, Glue P, Sweeney K et al (2007) Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clin Pharmacol Ther 81:377\u2013385","journal-title":"Clin Pharmacol Ther"},{"key":"798_CR71","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/2042098615613984","volume":"6","author":"D Garfinkel","year":"2015","unstructured":"Garfinkel D, Ilhan B, Bahat G (2015) Routine deprescribing of chronic medications to combat polypharmacy. Therap Adv Drug Safety 6:212\u2013233","journal-title":"Therap Adv Drug Safety"},{"key":"798_CR72","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1111\/j.1532-5415.2004.52563.x","volume":"52","author":"RM Carnahan","year":"2004","unstructured":"Carnahan RM, Lund BC, Perry PJ, Chrischilles EA (2004) The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc 52:2082\u20132087","journal-title":"J Am Geriatr Soc"},{"key":"798_CR73","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1532-5415.2008.01681.x","volume":"56","author":"KM Sink","year":"2008","unstructured":"Sink KM, Thomas J III, Xu H et al (2008) Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 56:847\u2013853","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"798_CR74","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s40266-013-0145-1","volume":"31","author":"C Tannenbaum","year":"2014","unstructured":"Tannenbaum C, Johnell K (2014) Managing therapeutic competition in patients with heart failure, lower urinary tract symptoms and incontinence. Drugs Aging 31(2):93\u2013101. https:\/\/doi.org\/10.1007\/s40266-013-0145-1","journal-title":"Drugs Aging"},{"key":"798_CR75","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00192-013-2259-8","volume":"25","author":"S Srikrishna","year":"2014","unstructured":"Srikrishna S, Robinson D, Cardozo L (2014) Important drug\u2013drug interactions for treatments that target overactive bladder syndrome. Int Urogynecol J 25:715\u2013720","journal-title":"Int Urogynecol J"},{"key":"798_CR76","first-page":"11","volume":"20","author":"A Athanasopoulos","year":"2011","unstructured":"Athanasopoulos A, Giannitsas K (2011) An overview of the clinical use of antimuscarinics in the treatment of overactive bladder. Adv Urol 20:11","journal-title":"Adv Urol"},{"key":"798_CR77","unstructured":"Trospium: Drug information, Lexicomp Online. In. 2022"},{"key":"798_CR78","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/ageing\/afaa249","volume":"50","author":"LJ Seppala","year":"2021","unstructured":"Seppala LJ, Petrovic M, Ryg J et al (2021) STOPPFall (screening tool of older persons prescriptions in older adults with high fall risk): a Delphi study by the EuGMS task and finish group on fall-risk-increasing drugs. Age Ageing 50:1189\u20131199","journal-title":"Age Ageing"},{"issue":"3","key":"798_CR79","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40266-022-00922-5","volume":"39","author":"F Pazan","year":"2022","unstructured":"Pazan F, Weiss C, Wehling M (2022) The FORTA (Fit fOR The Aged) list 2021: fourth version of a validated clinical aid for improved pharmacotherapy in older adults. Drugs Aging 39(3):245\u2013247. https:\/\/doi.org\/10.1007\/s40266-022-00922-5","journal-title":"Drugs Aging"},{"issue":"5","key":"798_CR80","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/ageing\/afv077","volume":"44","author":"M Oelke","year":"2015","unstructured":"Oelke M, Becher K, Castro-Diaz D, Chartier-Kastler E, Kirby M, Wagg A, Wehling M (2015) Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing 44(5):745\u2013755. https:\/\/doi.org\/10.1093\/ageing\/afv077","journal-title":"Age Ageing"},{"key":"798_CR81","doi-asserted-by":"crossref","unstructured":"Ha M, Furman A, Al Rihani SB et al (2022) Pharmacist\u2010driven interventions to de\u2010escalate urinary antimuscarinics in the Programs of All\u2010Inclusive Care for the Elderly. J Am Geriatr Soc","DOI":"10.1111\/jgs.17965"},{"key":"798_CR82","unstructured":"Deprescribing guide for anticholinergic drugs for urinary incontinence. The NSW Therapeutic Advisory Group. In. 2022."},{"key":"798_CR83","unstructured":"Gravas SC, Gacci JN, Gratzke M, Herrmann C, Mamoulakis TRW, Rieken C, Speakman M, Tikkinen MJ, KAO (2022) EAU guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). European Association of Urology 2022. In 2022 Edition"},{"key":"798_CR84","unstructured":"McVary KT (2022) Medical treatment of benign prostatic hyperplasia. In: O'Leary MPGJ (ed) Uptodate. pp 1\u20132"},{"key":"798_CR85","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.urology.2004.07.031","volume":"64","author":"B Djavan","year":"2004","unstructured":"Djavan B, Chapple C, Milani S, Marberger M (2004) State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 64:1081\u20131088","journal-title":"Urology"},{"key":"798_CR86","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/nau.20481","volume":"27","author":"MM Barendrecht","year":"2008","unstructured":"Barendrecht MM, Abrams P, Schumacher H et al (2008) Do \u03b11-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn 27:226\u2013230","journal-title":"Neurourol Urodyn"},{"key":"798_CR87","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387\u20132398","journal-title":"N Engl J Med"},{"key":"798_CR88","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0090-4295(01)01344-9","volume":"58","author":"P Boyle","year":"2001","unstructured":"Boyle P, Robertson C, Manski R et al (2001) Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 58:717\u2013722","journal-title":"Urology"},{"key":"798_CR89","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/sj.pcan.4500849","volume":"9","author":"C Roehrborn","year":"2006","unstructured":"Roehrborn C (2006) Three months\u2019 treatment with the \u03b11-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 9:121\u2013125","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"798_CR90","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.juro.2007.09.084","volume":"179","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn CG, Siami P, Barkin J et al (2008) The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 179:616\u2013621","journal-title":"J Urol"},{"key":"798_CR91","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","volume":"57","author":"CG Roehrborn","year":"2010","unstructured":"Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57:123\u2013131","journal-title":"Eur Urol"},{"key":"798_CR92","unstructured":"(2022) Duloxetin, terazosin, alfuzosin, silodosin: drug information, lexicomb. Online"},{"key":"798_CR93","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1742-1241.2009.02326.x","volume":"64","author":"CP Vaughan","year":"2010","unstructured":"Vaughan CP, Brown CJ, Goode PS et al (2010) The association of nocturia with incident falls in an elderly community-dwelling cohort. Int J Clin Pract 64:577\u2013583","journal-title":"Int J Clin Pract"},{"key":"798_CR94","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/nau.20712","volume":"28","author":"C Temml","year":"2009","unstructured":"Temml C, Ponholzer A, Gutjahr G et al (2009) Nocturia is an age-independent risk factor for hip-fractures in men. Neurourol Urodyn 28:949\u2013952","journal-title":"Neurourol Urodyn"},{"key":"798_CR95","first-page":"2","volume":"351","author":"B Welk","year":"2015","unstructured":"Welk B, McArthur E, Fraser L-A et al (2015) The risk of fall and fracture with the initiation of a prostate-selective \u03b1 antagonist: a population based cohort study. BMJ 351:2","journal-title":"BMJ"},{"key":"798_CR96","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1345\/aph.18263","volume":"34","author":"M Lee","year":"2000","unstructured":"Lee M (2000) Tamsulosin for the treatment of benign prostatic hypertrophy. Ann Pharmacother 34:188\u2013199","journal-title":"Ann Pharmacother"},{"key":"798_CR97","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1464-410X.2003.04309.x","volume":"92","author":"CG Roehrborn","year":"2003","unstructured":"Roehrborn CG, Van Kerrebroeck P, Nordling J (2003) Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 92:257\u2013261","journal-title":"BJU Int"},{"key":"798_CR98","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1016\/j.juro.2009.02.034","volume":"181","author":"LS Marks","year":"2009","unstructured":"Marks LS, Gittelman MC, Hill LA et al (2009) Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 181:2634\u20132640","journal-title":"J Urol"},{"key":"798_CR99","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/j.1742-1241.2008.01880.x","volume":"62","author":"J Nickel","year":"2008","unstructured":"Nickel J, Sander S, Moon T (2008) A meta-analysis of the vascular-related safety profile and efficacy of \u03b1-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 62:1547\u20131559","journal-title":"Int J Clin Pract"},{"key":"798_CR100","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1464-410X.2005.05487.x","volume":"95","author":"MM Barendrecht","year":"2005","unstructured":"Barendrecht MM, Koopmans RP, De La Rosette JJ, Michel MC (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 95:19\u201328","journal-title":"BJU Int"},{"key":"798_CR101","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1016\/j.juro.2006.07.154","volume":"176","author":"T Nieminen","year":"2006","unstructured":"Nieminen T, Tammela TL, Koobi T, Kahonen M (2006) The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. J Urol 176:2551\u20132556","journal-title":"J Urol"},{"key":"798_CR102","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.eururo.2010.10.046","volume":"59","author":"CR Chapple","year":"2011","unstructured":"Chapple CR, Montorsi F, Tammela TL et al (2011) Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 59:342\u2013352","journal-title":"Eur Urol"},{"key":"798_CR103","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bju.12712","volume":"114","author":"G Novara","year":"2014","unstructured":"Novara G, Chapple CR, Montorsi F (2014) A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). BJU Int 114:427\u2013433","journal-title":"BJU Int"},{"key":"798_CR104","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/j.1464-410X.2011.10233.x","volume":"108","author":"HJ Yu","year":"2011","unstructured":"Yu HJ, Lin ATL, Yang SSD et al (2011) Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). BJU Int 108:1843\u20131848","journal-title":"BJU Int"}],"container-title":["European Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-023-00798-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41999-023-00798-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41999-023-00798-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T06:44:00Z","timestamp":1702536240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41999-023-00798-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,28]]},"references-count":104,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["798"],"URL":"https:\/\/doi.org\/10.1007\/s41999-023-00798-7","relation":{},"ISSN":["1878-7657"],"issn-type":[{"value":"1878-7657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,28]]},"assertion":[{"value":"7 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study does not contain any studies with human participants performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}